Rappta Therapeutics enters into a global license agreement with SpringWorks Therapeutics for a pre-clinical first-in-class molecular glue targeting PP2A

Posted on by

Goal to accelerate development and commercialization of the lead asset RPT04402 for the treatment of a subset of uterine cancers Financials include a $13 million upfront payment and potential for significant further milestones HELSINKI, Jan. 13, 2025 /PRNewswire/ — Rappta Therapeutics…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.